Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Does the Glucagon-like Peptide-1 Receptor Agonist Semaglutide Prevent Deterioration of Metabolic State in Prediabetic or Diabetic Patients With Schizophrenia Treated With the Antipsychotic Compounds Clozapine or Olanzapine?

NCT04892199 is registered in ClinicalTrials.gov with Anders Fink-Jensen, MD, DMSci as lead sponsor.

NCT NCT04892199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04892199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Does the Glucagon-like Peptide-1 Receptor Agonist Semaglutide Prevent Deterioration of Metabolic State in Prediabetic or Diabetic Patients With Schizophrenia Treated With the Antipsychotic Compounds Clozapine or Olanzapine?
Lead sponsor
Anders Fink-Jensen, MD, DMSci
Phase
Phase 4
Overall status
Active, not recruiting
Start date
September 1, 2021
Completion date
August 1, 2026
Enrollment
104 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

clozapine, glp-1, metabolic disturbance, olanzapine, schizophrenia, type 2 diabetes